OraSure Technologies Signs Purchase Contract with New York City Department of Mental Health and Hygiene for OraQuick(R) ADVANCE
27 Giugno 2006 - 3:35PM
Business Wire
OraSure Technologies, Inc. (NASDAQ:OSUR), the market leader in oral
fluid diagnostics, today announced that it has entered into an
approximate $6 million, multi-year purchase contract with the New
York City Department of Mental Health and Hygiene to expand the use
of OraQuick(R) ADVANCE(TM) Rapid HIV-1/2 Antibody Tests in the
City. The contract will commence on July 1, 2006, and will extend
New York City's aggressive program of HIV prevention, which
includes widespread access to voluntary rapid HIV testing and HIV
prevention and education initiatives throughout the City. OraSure
has already donated 1,000 OraQuick(R) ADVANCE(TM) tests to the City
in honor of National HIV Testing Day, commemorated annually on June
27th. OraSure President and Chief Executive Officer, Douglas A.
Michels, and the Assistant Commissioner for Health for the New York
City Department of Health, Scott Kellerman, M.D., will announce the
new contract at The NASDAQ Market Open Ceremony this morning in New
York City. According to the New York City Department of Mental
Health and Hygiene, more than 100,000 New Yorkers are living with
HIV, but thousands do not know that they are infected. As a result,
many infected individuals do not receive the care they need to stay
healthy and unknowingly spread HIV in their community. "We are
pleased to expand the availability of our OraQuick(R) ADVANCE(TM)
test in New York City, to help stop the HIV epidemic through
increased testing," said Douglas A. Michels, President and Chief
Executive Officer of OraSure Technologies. "Making rapid HIV
testing widely available has been shown to increase the likelihood
that people will get tested and promptly learn their status so that
they can receive any necessary treatment and counseling as soon as
possible. By ensuring that increased testing is available to in New
York as well as other cities, we expect to make significant strides
in beating this disease." Providing results in as little as 20
minutes, OraQuick(R) ADVANCE(TM) is the only rapid, point-of-care
test for the detection of antibodies to both HIV-1 and HIV-2
approved by the U.S. Food and Drug Administration (FDA) for use on
oral fluid, finger stick or venipuncture whole blood, and plasma
specimens. The test is also CLIA (Clinical Laboratory Improvements
Amendments Act of 1988) waived for all specimen types except
plasma. OraSure Technologies commercially launched the OraQuick(R)
ADVANCE(TM) test in October 2004. Now in its 12th year, National
HIV Testing Day is an annual event led by the National Association
of People with AIDS (NAPWA) to encourage the millions of Americans
who are at-risk for HIV to receive voluntary HIV counseling and
testing. According to the Centers for Disease Control and
Prevention (CDC), as many as one-third of the estimated one million
HIV-infected people in the United States may be unaware that they
are infected with the HIV virus - and 55 percent of new
transmissions of HIV are derived from individuals who are unaware
of their positive status. About OraSure Technologies OraSure
Technologies develops, manufactures and markets oral fluid specimen
collection devices using proprietary oral fluid technologies,
diagnostic products including immunoassays and other in vitro
diagnostic tests, and other medical devices. These products are
sold in the United States as well as internationally to various
clinical laboratories, hospitals, clinics, community-based
organizations and other public health organizations, distributors,
government agencies, physicians' offices, and commercial and
industrial entities. OraSure Technologies is the leading supplier
of oral-fluid collection devices and assays to hospitals, the life
insurance industry and public health markets for the detection of
HIV. In addition, the Company supplies oral-fluid testing solutions
for drugs of abuse testing. For more information on the Company,
please go to http://www.orasure.com. Important Information This
press release contains certain forward-looking statements,
including with respect to product purchases and testing
initiatives. Actual results could be significantly different.
Factors that could affect results include the ability to market
products; impact of competitors, competing products and technology
changes; ability to develop, commercialize and market new products;
market acceptance of oral fluid testing or other products and
changes in market acceptance based on product performance;
continued bulk purchases by customers, including governmental
agencies, and the ability to fully deploy those purchases in a
timely manner; ability to fund research and development and other
products and operations; ability to obtain and maintain new or
existing product distribution channels; reliance on sole supply
sources for critical product components; availability of related
products produced by third parties; ability to obtain, and timing
of obtaining, necessary regulatory approvals; ability to comply
with applicable regulatory requirements; history of losses and
ability to achieve sustained profitability; volatility of our stock
price; uncertainty relating to patent protection and potential
patent infringement claims; uncertainty and costs of litigation
relating to patents and other intellectual property; availability
of licenses to patents or other technology; ability to enter into
international manufacturing agreements; obstacles to international
marketing and manufacturing of products; ability to sell products
internationally; loss or impairment of sources of capital; ability
to meet financial covenants in agreements with financial
institutions; ability to retain qualified personnel; exposure to
product liability, patent infringement, and other types of
litigation; changes in international, federal or state laws and
regulations; changes in relationships with strategic partners and
reliance on strategic partners for the performance of critical
activities under collaborative arrangements; customer
consolidations and inventory practices; equipment failures and
ability to obtain needed raw materials and components; the impact
of terrorist attacks and civil unrest; ability to complete
consolidation or restructuring activities; ability to identify,
complete and realize the full benefits of potential acquisitions;
and general political, business and economic conditions. These and
other factors are discussed more fully in the Securities and
Exchange Commission ("SEC") filings of OraSure Technologies,
including its registration statements, its Annual Report on Form
10-K for the year ended December 31, 2005, its Quarterly Reports on
Form 10-Q, and its other filings with the SEC. Although
forward-looking statements help to provide complete information
about future prospects, readers should keep in mind that
forward-looking statements may not be reliable. The forward-looking
statements are made as of the date of this press release and
OraSure Technologies undertakes no duty to update these statements.
Grafico Azioni OraSure Technologies (NASDAQ:OSUR)
Storico
Da Set 2024 a Ott 2024
Grafico Azioni OraSure Technologies (NASDAQ:OSUR)
Storico
Da Ott 2023 a Ott 2024